“Global Blood Cancer market set to grow to $35bn by 2024” says new Visiongain report

11 April 2019
Pharma

Visiongain has published a new pharma report Global Blood Cancer Market Report : Immunotherapy, Chemotherapy, Targeted Therapy.

The global blood cancer market reached $24bn in 2018 and is estimated to grow at a CAGR of 6.4% in the first half of the forecast period. Chemotherapy held 44% of the market in 2018. The changing demographics of the world population, developing infrastructure, emerging economies, consumer spending behaviour, per capita income, macroeconomic factors, rising GDPs, and the reformation in laws and regulations are trend setting factors, which will affect the market.

This report profiled the selected companies: Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb (BMS), Celgene and other companies.

The lead analyst commented that "Chemotherapy will continue to be the largest segment for therapy of cancer; however, the huge effort for a breakthrough in cancer treatment will result in the growth of targeted cell therapy as well as immunotherapy segments. High income countries will see more growth in this novel type of therapy when compared to the developing nations due to the high cost of the treatment. Blood cancer market is expected to grow as the number of cases would increase due to non-availability of the perfect treatment options."

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2021-2031

Contract manufacturing outsourcing is gaining attraction owing to growing trend of outsourcing among pharmaceutical businesses.

16 November 2021

Read

Visiongain Publishes Biosimilars and Follow-On Biologics Market Report 2021-2031

The potential for digital & analytics applications in the pharmaceutical and biotechnology sector has grown dramatically in recent years as a result of fast technological advances as well as changes in the market environment & stakeholder behaviour as a result of the pandemic.

04 November 2021

Read

Visiongain Publishes Pharmaceutical Spray Drying Market Report 2021-2031

The rising prevalence of oncological disorders, lung infections, rising demand for customised drugs coupled with new orphan diseases discoveries, are few of the major reasons responsible for development of pharmaceutical spray drying market.

25 October 2021

Read

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever